Investigation Of Anti – Inflammatory Activity Of Mesalamine Loading Silica Redox Nanoparticles

Abstract

The most widespread and severe forms of idiopathic inflammatory bowel disease (IBD) are Crohn's disease (CD) and ulcerative colitis (UC). There are now no approved medical treatments for these disorders, and their pathophysiology is not fully understood. Through a number of inflammatory mechanisms, chronic inflammation, and excessive reactive oxygen species (ROS) generation have been linked together. There are numerous pharmaceutical treatments for reducing intestinal inflammation, including the use of antiinflammatory drugs such as mesalamine. The majority of anti-inflammatory drugs are poorly absorbed and have a low bioavailability, which decreases their therapeutic effectiveness and amplifies their adverse effects when taken for a long time. Numerous pharmaceutical delivery systems have been invented with the use of nanotechnology, however, the majority of them have expensive production costs and are challenging to mass produce. This study's aim was to explore silica-containing redox particles (siRNPs) made from an amphiphilic block copolymer that has a drug-absorbent silica moiety and a ROS-scavenging nitroxide radical moiety in the hydrophobic segment. To improve the stability and regulate the drug's release into the digestive system, this method was researched. Using the dialysis approach, mesalamine-loaded siRNP (MES@siRNP) with a diameter of around 120 nm was used as a nanocarrier for mesalamine. By using the 2,2'-azinobis(3-ethylebenzothiaziline-6-sulfonate) (ABTS) and 2,2'-diphenyl-1-picrylhydrazyl (DPPH) assays, MES@siRNP samples displayed antioxidant activity. A lipopolysaccharide-induced macrophage cell line activation and albumin denaturation paradigm were used to assess the anti-inflammatory activity in vitro. A new anti-inflammation nano-formulation with this combination showed promise and merits of future study.